Hydroxy-substituted sphingolipids
Patent Information
- Application Number
- JP2023541054
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-01-06
- Filing Date
- 2022-01-05
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2042-01-05
AI Technical Summary
There is a need for substances that can reduce or prevent signs of skin aging caused by solar radiation, particularly by inhibiting the formation of reactive oxygen species (ROS) and protecting against UV-induced DNA damage.
Hydroxy-substituted sphingolipids, such as hydroxybutyroylphytosphingosine, succinoylphytosphingosine, gluconoylphytosphingosine, lactobionoylphytosphingosine, and 2-hydroxy-3,3-dimethyl-hydroxybutyroylphytosphingosine, are used in cosmetic formulations to provide protective effects against UV-induced damage and enhance skin barrier function.
These sphingolipids effectively inhibit ROS formation and protect against UV-induced DNA damage, improving skin brightness, reducing roughness, and increasing skin density, with demonstrated efficacy in both in vitro and in vivo studies.
Smart Images

Figure 2022148758000001 
Figure 2022148758000002 
Figure 2022148758000003
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention provides hydroxy-substituted sphingolipids, their preparation and uses, as well as cosmetic formulations in which they are components.
[0002] Prior Art The aim of care cosmetics is to maintain a youthful appearance, for example of the skin and hair. There are in principle different ways to achieve this. For example, existing damage to the skin, such as irregular pigmentation or wrinkles, can be corrected by means of concealing powders or creams.
[0003] Another approach is to protect the skin from environmental influences that cause permanent damage and thus aging of the skin. The idea is therefore to intervene preventatively and thereby slow down the aging process.
[0004] The most important function of the skin is to protect the body from uncontrolled water leakage on the one hand and from invasion by harmful chemicals or bacteria and from the sun's rays on the other hand. Prolonged exposure of human skin to sunlight can lead to photoinduced aging of the skin and / or the development of pigmentation disorders.
[0005] This harmful effect of sunlight is due in particular to UVB radiation (280-320 nm) present in the solar spectrum.
[0006] There is an ongoing search for skin care substances that can reduce or even prevent the development of signs of skin aging, particularly those caused by solar exposure.
[0007] FR 2 855 049 discloses 6-hydroxy-sphingenine-based ceramides for strengthening the skin barrier. FR 2 874 610 discloses N-dihydroxyalkylhydroxyalkanamide derivatives and their use in cosmetics.
[0008] The object of the present invention is to provide a substance which reduces the signs of aging caused by solar radiation.
[0009] Description of the invention Surprisingly, it has been found that the ceramide derivatives described below are able to achieve the object of the invention and inhibit the formation of reactive oxygen species (ROS) caused by UV light.
[0010] Thus, the present invention provides certain hydroxy-substituted sphingolipids and their production and uses.
[0011] The present invention further provides cosmetic formulations comprising the above-described hydroxy-substituted sphingolipids.
[0012] An advantage of the sphingolipids of the present invention is their protective effect against DNA damage, especially UV-induced damage, especially in the skin.
[0013] Another advantage of the sphingolipids of the present invention is their thickening effect, especially in cosmetic formulations.
[0014] Thus, the present invention relates to compounds of the general formula I [ka] [In the formula, R 1 is a hydrocarbon group having 2 to 54, preferably 2 to 30, more preferably 2 to 18 carbon atoms, substituted with at least one group selected from -OH and -COOH and optionally interrupted by at least one -O-; R 2is H, phosphocholine, serine, ethanolamine or a sugar, preferably a sugar or H, more preferably H; X is CH=CH, CH2-CH2 or CH2-HCOH, preferably CH2-HCOH; Y is selected from -OH and H; However, R 1 When X is a straight-chain alkyl group substituted only with -OH groups at the ω position, X is CH2-HCOH.
[0015] The sphingolipids of general formula I have multiple stereocenters, all of which are covered by general formula I.
[0016] Unless otherwise stated, all percentages (%) listed are by weight.
[0017] Preferred sphingolipids of the present invention are R 1 is preferably selected from linear or branched alkyl groups having 2 to 54, preferably 2 to 30, more preferably 2 to 18 carbon atoms substituted with at least one group selected from -OH and -COOH, and is preferably R 2 , Y is H, particularly preferably X is CH2-HCOH It is characterized by:
[0018] In a preferred embodiment of the present invention, R 1 The alkyl group is preferably linear.
[0019] Further preferred sphingolipids of the present invention are R 1 is preferably selected from a hydrocarbon group having 2 to 54, preferably 2 to 30, more preferably 2 to 18 carbon atoms substituted at the ω-position with at least one group selected from -OH and -COOH, and is preferably R 2, Y is H, particularly preferably X is CH2-HCOH It is characterized by:
[0020] In a preferred embodiment of the present invention, R 1 The hydrocarbon group is preferably linear.
[0021] A particularly preferred sphingolipid of the present invention is hydroxybutyroylphytosphingosine. [ka] , succinoylphytosphingosine [ka] , gluconoyl phytosphingosine [ka] , Lactobionoyl phytosphingosine [ka] , and 2-hydroxy-3,3-dimethyl-hydroxybutyroylphytosphingosine [ka] is selected from.
[0022] Since the sphingolipids of the present invention exhibit excellent therapeutic effects, the present invention further provides the sphingolipids of the present invention for use in the treatment, in particular for use in the prevention, of cell damage, preferably cell damage induced by UV radiation, in particular skin cell damage, wherein the cell damage according to the present invention is preferably DNA damage.
[0023] The sphingolipids of the invention can also be used in purely cosmetic applications, and the invention therefore further provides the cosmetic, non-therapeutic use of at least one sphingolipid of the invention for preventing skin aging caused by UV radiation.
[0024] The sphingolipids of the present invention can be easily incorporated into cosmetic formulations. The present invention therefore further provides a cosmetic formulation comprising at least one sphingolipid of the present invention, preferably in an amount of 0.02% to 1.50% by weight, preferably 0.03% to 1.00% by weight, more preferably 0.05% to 0.50% by weight, the weight percentages being based on the total formulation.
[0025] The cosmetic formulations according to the invention are in particular sunscreen formulations and therefore preferably contain UV photoprotective filters.
[0026] Thus, a preferred formulation of the present invention comprises: At least one sphingolipid of the invention, and At least one UV light protection filter substance It includes.
[0027] The UV light protection filters used may, for example, be organic substances capable of absorbing ultraviolet radiation and then re-emitting the absorbed energy in the form of longer wave radiation, for example heat.
[0028] UVB filters may be oil-soluble or water-soluble. Examples of oil-soluble UVB photoprotective filters include: 3-benzylidene camphor and its derivatives, such as 3-(4-methylbenzylidene) camphor, 4-aminobenzoic acid derivatives, such as 2-ethylhexyl 4-(dimethylamino)benzoate and amyl 4-(dimethylamino)benzoate; Esters of cinnamic acid, such as 2-ethylhexyl 4-methoxycinnamate, isopentyl 4-methoxycinnamate, 2-ethylhexyl 2-cyano-3-phenylcinnamate (octocrylene); Esters of salicylic acid, such as 2-ethylhexyl salicylate, 4-isopropylbenzyl salicylate, homomenthyl salicylate, Derivatives of benzophenone, such as 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, Esters of benzalmalonic acid, such as di-2-ethylhexyl 4-methoxybenzmalonate, triazine derivatives, such as 2,4,6-trianilino-(p-carbo-2'-ethyl-1'-hexyloxy)-1,3,5-triazine, octyl triazone, and those described in EP 1 180 359 and DE 2004 / 027 475, Propane-1,3-diones, such as 1-(4-tert-butylphenyl)-3-(4'-methoxyphenyl)propane-1,3-dione.
[0029] Suitable water-soluble UVB photoprotective filters include: 2-Phenylbenzimidazole-5-sulfonic acid and its alkali metal, alkaline earth metal, ammonium, alkylammonium, alkanolammonium and glucanammonium salts, Sulfonic acid derivatives of benzophenone, such as 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and their salts, Sulfonic acid derivatives of 3-benzylidenecamphor, such as 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid and 2-methyl-5-(2-oxo-3-bornylidene)sulfonic acid and their salts.
[0030] Suitable typical UVA photoprotective filters include, in particular, derivatives of benzoylmethane, such as 1-(4'-tert-butylphenyl)-3-(4'-methoxyphenyl)propane-1,3-dione or 1-phenyl-3-(4'-isopropylphenyl)propane-1,3-dione. Of course, it is also possible to use mixtures of UV-A and UV-B filters.
[0031] In addition to the soluble substances mentioned, insoluble pigments, i.e. finely dispersed metal oxides or salts, such as titanium dioxide, zinc oxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talc), barium sulfate and zinc stearate, are also suitable for this purpose. Herein, the particles should have an average diameter of less than 100 nm, for example 5-50 nm, in particular 15-30 nm. They may be spherical, but it is also possible to use particles which are ellipsoidal or have a shape which deviates from spherical in some other way. A relatively new class of light protection filters is that of finely divided organic pigments, for example 2,2'-methylenebis{6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol}, with a particle size of less than 200 nm, obtained, for example, as a 50% aqueous dispersion.
[0032] Further suitable UV light protection filters can be found in the review by P. Finkel in the SOEFW-Journal 122, 543 (1996).
[0033] In connection with the formulations according to the invention, said formulations preferably contain lipophilic hydrophobic UV light protection filter substances, in particular triazine derivatives, whereby as UV-B filters there are UV light protection filter substances 2-ethylhexyl 2-cyano-3-phenylcinnamate, 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine, dioctylbutyramido triazone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, di-2-ethylhexyl 4-methoxybenzmalonate, 2,4,6-tris-[anilino It is particularly preferable to use -(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine, 2,4-bis[5,1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imino]-6-(2-ethylhexyl)imino-1,3,5-triazine, 2,4-bis-{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine and 2-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl]-5-(octyloxy)phenol.
[0034] The UV-A filters used are preferably 1-(4'-tert-butylphenyl)-3-(4'-methoxyphenyl)propane-1,3-dione, 1-phenyl-3-(4'-isopropylphenyl)propane-1,3-dione.
[0035] Particularly preferred UV-A filters are 4-(tert-butyl)-4'-methoxydibenzoylmethane (CAS No. 70356-09-1), sold under the brand Parsol® 1789 by DSM and under the trade name Eusolex® 9020 by Merck, and hydroxybenzophenones according to DE 102004027475 A1, particularly preferably hexyl 2-(4'-diethylamino-2'-hydroxybenzoyl)benzoate (also aminobenzophenone), available under the name Uvinul A Plus from BASF.
[0036] Further preferred UV filter substances are further so-called broadband filters, i.e. filter substances which absorb both UV-A and UV-B radiation.Within this group, preference is given to using 2,2'-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol), available under the trade name Tinosorb® M from Ciba Chemikalien GmbH, and 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]phenol (CAS No.: 155633-54-8), which has the INCI name Drometrizole Trisiloxane.
[0037] In addition to the two groups of primary UV photoprotective filters mentioned above, it is also possible to use secondary light stabilizers of the antioxidant type which intercept the photochemical reaction chains initiated when UV radiation penetrates the skin.
[0038] The cosmetic formulations according to the invention preferably contain UV photoprotective filters in an amount of from 0.01% to 15% by weight, preferably from 0.05% to 10% by weight, more preferably from 0.1% to 5% by weight, based on the total formulation.
[0039] Preferably, the cosmetic formulations according to the invention contain a combination of two or more different UV photoprotective filters.
[0040] If both UVA and UVB photoprotective filters are used in the formulations according to the invention, the weight ratio of these filters is preferably between 1:2 and 1:4.
[0041] The formulations of the present invention may further comprise at least one additional ingredient selected from the following group: Emollients, emulsifier, Thickeners / viscosity modifiers / stabilizers, Antioxidants, Hydrotropes (or polyols), Solids and fillers, Film formers, Pearlescent additives, Deodorant and antiperspirant actives, Insect repellent, Self-tanning agents, Preservatives, Adjusting agent, fragrance, dye, Odor absorbers, cosmetic active substances, Care Additives, Superfatting agents, solvent.
[0042] Substances that can be used as exemplary representatives of the individual groups are known to the person skilled in the art and can be found, for example, in DE 102008001788 A1, which is incorporated herein by reference and thus constitutes part of the present disclosure.
[0043] With regard to further optional ingredients and the amounts of these ingredients to be used, explicit reference is made to relevant handbooks known to those skilled in the art, such as, for example, K. Schrader, “Grundlagen und Rezepturen der Kosmetika” [Fundamentals and formulations of cosmetics], 2nd edition, pages 329 to 341, Huethig Buch Verlag Heidelberg.
[0044] The amount of each additive is guided by the intended use.
[0045] Typical frame formulations for specific applications are known in the prior art and are included, for example, in the brochures of manufacturers of specific base materials and active ingredients. These existing formulations can generally be adopted without modification. However, if adjustments and optimization are required, the desired modifications can be easily carried out through simple testing.
[0046] The present invention further relates to a method for producing sphingolipids, in particular a method for producing the sphingolipids of the present invention, comprising the steps of: I) a first component, represented by general formula II [ka] [In the formula, R 2b is H, phosphocholine, serine, ethanolamine or a sugar, preferably a sugar or H, more preferably H; X b is CH=CH, CH2-CH2 or CH2-HCOH, preferably CH2-HCOH; II) a second component of formula R 1b C.Y. b HCOOH [In the formula, R 1bis a hydrocarbon group having 2 to 54, preferably 2 to 30, more preferably 2 to 18 carbon atoms, substituted with at least one group selected from -OH and -COOH and optionally interrupted by at least one -O-; Y b is selected from -OH and H; III) reacting the first component with the second component to obtain a sphingolipid, and optionally IV) Purifying sphingolipids The present invention provides a method comprising:
[0047] The process of the present invention is preferably characterized in that process step III) is carried out within a temperature range of 40°C to 95°C, preferably 50°C to 80°C, more preferably 60°C to 70°C.
[0048] The present invention further relates to an alternative method for producing sphingolipids, in particular for producing sphingolipids according to the invention, comprising the following method steps: A) a first component, represented by general formula II [ka] [In the formula, R 2b is H, phosphocholine, serine, ethanolamine or a sugar, preferably a sugar or H, more preferably H; X b is CH=CH, CH2-CH2 or CH2-HCOH, preferably CH2-HCOH; B) The second component, formula R 1b C.Y. b HCOOH [In the formula, R 1bis a hydrocarbon group having 2 to 54, preferably 2 to 30, more preferably 2 to 18 carbon atoms, substituted with at least one group selected from -OH and -COOH and optionally interrupted by at least one -O-; Y b is selected from -OH and H; C) reacting the first component with the second component using at least one coupling reagent for activation of the hydroxycarboxylic acid to obtain a sphingolipid, and optionally D) Purifying sphingolipids The present invention provides a method comprising:
[0049] An alternative process according to the invention is preferably characterized in that in process step C) the coupling reagent used is at least one selected from the group comprising, preferably consisting of, dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-cyclohexyl-N'-(2'-morpholinoethyl)carbodiimide metho-p-toluenesulfonate, N-benzyl-N'-3'-dimethylaminopropylcarbodiimide hydrochloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N-ethylcarbodiimide hydrochloride and carbonyldiimidazole, particularly preferably dicyclohexylcarbodiimide and diisopropylcarbodiimide.
[0050] The alternative process according to the invention is preferably characterized in that in process step C) at least one catalyst is used which is selected from the group comprising, preferably consisting of, N-ethyldiisopropylamine, trialkylamines, pyridine, 4-dimethylaminopyridine and hydroxybenzotriazoles, in particular hydroxybenzotriazoles.
[0051] The method of the invention is preferably characterized in that method step C) is carried out within a temperature range of 40°C to 95°C, preferably 50°C to 80°C, more preferably 55°C to 65°C.
[0052] The preferred methods according to the invention preferably result in the sphingolipids described above as preferred according to the invention.
[0053] The following examples are provided to illustratively explain the present invention, and are not intended to limit the present invention, the scope of which is clear from the entire specification and claims, to the embodiments specified in the examples. [Brief description of the drawings]
[0054] The following drawings form part of the examples: [Figure 1] FIG. 1 shows the production of ROS after UV irradiation. [Diagram 2] FIG. 1 shows DNA damage after UV irradiation. [Diagram 3] FIG. 1 shows the increase in ITA° after 2, 4 and 8 weeks of application of test formulations. [Figure 4] FIG. 1 shows the increase in L* after 2, 4 and 8 weeks of application of test formulations. [Diagram 5] FIG. 1 shows the reduction in skin roughness after 2, 4 and 8 weeks of application of test formulations. [Figure 6] FIG. 1 shows the increase in skin density after 2, 4 and 8 weeks of application of test formulations.
[0055] Working Example: Example 1: 4-Hydroxybutyroylphytosphingosine Phytosphingosine and γ-butyrolactone are dissolved in methanol in a molar ratio of 1:1. The mixture is reacted at 65° C. until phytosphingosine is no longer detectable. Cooling to room temperature gives crystals of 4-hydroxybutyroylphytosphingosine, which are filtered off with suction and washed with a 1:1 THF / water mixture. The yield is greater than 80% and the purity is greater than 90%.
[0056] Example 1b: 6-Hydroxyhexanoyl Phytosphingosine Phytosphingosine and ε-caprolactone are dissolved in methanol in a molar ratio of 1:1. The mixture is reacted at 65° C. until phytosphingosine is no longer detectable. After cooling to room temperature, crystals of 6-hydroxyhexanoyl phytosphingosine are obtained, which are filtered off with suction and washed with a 1:1 THF / water mixture. The yield is greater than 80% and the purity is greater than 90%.
[0057] Example 1c (not according to the invention): 3-hydroxypropioylphytosphingosine Phytosphingosine and β-propiolactone are dissolved in methanol in a 1:1 molar ratio. The mixture is reacted at 65° C. until phytosphingosine is no longer detectable. Cooling to room temperature gives crystals of 3-hydroxypropioylphytosphingosine, which are filtered with suction and washed with a 1:1 THF / water mixture. The yield is greater than 80% and the purity is greater than 90%.
[0058] Example 2: Succinoyl phytosphingosine Phytosphingosine and succinic anhydride are dissolved in methanol in a molar ratio of 1:1. The mixture is reacted at 65° C. until phytosphingosine is no longer detectable. Cooling to room temperature gives succinoyl phytosphingosine crystals, which are filtered with suction and washed with a 1:1 THF / water mixture. The yield is greater than 80% and the purity is greater than 90%.
[0059] Example 3: Gluconoyl Phytosphingosine Phytosphingosine and d-gluconolactone are dissolved in methanol in a molar ratio of 1:1. The mixture is reacted at 65°C until phytosphingosine is no longer detectable. Workup is performed by gradually lowering the temperature to 10°C for crystallization. The product is filtered using vacuum and washed with ethanol. After drying to constant weight, the yield is greater than 80% and the purity is greater than 90%.
[0060] Example 4: Lactobionoyl phytosphingosine 71.66 g of lactobionic acid and 75.44 g of phytosphingosine are dissolved in dimethylformamide (DMF). 2 g of N-hydroxysuccinimide (HSU) and 15 ml of N,N-diisopropylcarbodiimide (DIC) are added and the mixture is reacted at 60° C. for 2 hours. The residual DIC is quenched by adding 15 ml of water and reacting the mixture for another ½ hour. For workup, the dimethylformamide is distilled off and the product residue is then dissolved in methanol. The product is then crystallized by slowly cooling to 10° C. The product thus obtained is filtered, washed with methanol and dried. The yield is greater than 80% and the purity is greater than 90%.
[0061] Example 5: 2-Hydroxy-3,3-dimethyl-hydroxybutyroylphytosphingosine Phytosphingosine and D-pantolactone are dissolved in ethanol in a molar ratio of 1:1. The mixture is reacted at 60° C. for 8 hours. The product is then crystallized by slowly cooling to 10° C. It is then filtered and dried. The yield is greater than 80% and the purity is greater than 90%.
[0062] Example 5b: 2-Hydroxy-3,3-dimethyl-hydroxybutyroylsphinganine Sphinganine and D-pantolactone are dissolved in ethanol in a molar ratio of 1:1. The mixture is reacted at 60° C. for 8 hours. The product is then crystallized by slowly cooling to 10° C. It is then filtered and dried. The yield is greater than 80% and the purity is greater than 90%.
[0063] Example 6: Prevention against UV damage The extent to which the substances of the invention are able to exert a protective effect on normal human epidermal keratinocytes (NHEK) exposed to UV radiation was investigated.
[0064] For this, corresponding investigations were performed on biomarkers of reactive oxygen species (ROS) quantified with 2,7-dichlorodihydrofluorescein diacetate and DNA damage and repair quantified by the comet assay.
[0065] Reactive oxygen species (ROS) The intracellular formation of reactive organic species (ROS) is, among other factors, a factor that leads to cellular DNA damage by UV irradiation.
[0066] Keratinocytes were seeded in 96-well plates and cultured for 24 hours in culture medium and then for another 24 hours in assay medium. The medium was then replaced with test medium containing test compounds or references (vitamin E 100 μM and EGCG 10 μM) or in their absence (irradiated control) and the cells were pre-incubated for 24 hours. After pre-incubation, the medium was removed and replaced with assay medium, the fluorescent probe (2,7-dichlorodihydrofluorescein diacetate (10 μM 2,7-DCDHF-DA in assay medium)) was added and the cells were incubated for 30 minutes at 37°C. The cells were then washed with PBS solution and incubated with 100 mJ / cm2 without compounds or references. 2 UVB+UVA(+0.7J / cm 2) The lamp used was a SOL500 solar simulator (Dr. Hoenle, AG) equipped with an H2 filter. After irradiation, the cells were incubated for 30 min. Unirradiated controls and conditions without sample (background noise) were run in parallel.
[0067] All experimental conditions were performed in triplicate.
[0068] Fluorescence emission intensity (ex=485 nm, em=538 nm) was measured using an EnVision® (PerkinElmer) microplate reader.
[0069] The fluorescence intensity of metabolic samples (DCF) was proportional to the formation of ROS, therefore, ROS production was expressed as the relative intensity of fluorescence.
[0070] FIG. 1 shows the corresponding results.
[0071] It is found that the production of reactive oxygen species (ROS) in human epidermal keratinocytes is induced by irradiation with UV light (corresponding to a protective effect of 0%). The vitamin E and epigallocatechin gallate (EGCG) positive controls used in this study are known to have a protective effect against UV irradiation and therefore show a protective effect of 30-40% against the formation of ROS. The used substances of the invention likewise show a substantial protective effect, exceeding 40% as the concentration increases. Such an effect has not been reported so far for sphingolipids / ceramides.
[0072] The sphingoid base phytosphingosine (PS) was also tested as a base, and no significant preventive effect was observed.
[0073] The following experiments are not shown in Figure 1: In the above setting, 2-hydroxy-3,3-dimethyl-hydroxybutyroylsphinganine exhibits a 22% protective effect at a concentration of 5 μM, and 2-hydroxy-3,3-dimethyl-hydroxybutyroylphytosphingosine exhibits a 38% protective effect at a concentration of 5 μM.
[0074] In the above setting, ceramide 3 (also known as ceramide NP) exhibits a 4% protective effect at a concentration of 10 μM, and 3-hydroxypropioylphytosphingosine exhibits a 5% protective effect at a concentration of 10 μM.
[0075] DNA Damage and Repair Keratinocytes were seeded in 6-well plates and incubated for 48 hours in culture medium, which was replenished after 24 hours. The medium was then replaced with culture medium containing the test compound or reference (0.3 mM control) or in their absence (control), and the cells were incubated for 24 hours. After preincubation, the culture medium was removed and assay medium was added again, and the cells were incubated for 24 hours at 250 mJ / cm in the absence of compound. 2 UVB+UVA(+1.6J / cm 2 ) for 10 min. The lamp used was a SOL500 solar simulator (Dr. Hoenle, AG) equipped with an H2 filter. An unirradiated control condition was run in parallel. All experimental conditions were performed in duplicate.
[0076] At the end of irradiation, culture supernatants were discarded and cells were washed with phosphate-buffered saline (PBS) before analysis.
[0077] The cells were trypsinized and counted, and the supernatant was removed after centrifugation. The cells were then washed with PBS solution until the cell concentration was 1 × 10 5The cells were suspended in the same PBS solution at 1000 cells / ml. The cell suspension was then mixed with molten (37°C) 1% low melting point agarose gel and pipetted onto a Comet microscope slide (duplicate analysis for each condition). For cell lysis, the microscope slide was immersed in an alkaline solution (200 mM NaOH containing 1 mM EDTA, pH>13) freshly prepared on the electrophoresis support. Gel electrophoresis was performed at 21 volts for 30 minutes. The Comet microscope slide was washed twice with water for 5 minutes each time, then with 70% ethanol for 5 minutes and air-dried at 37°C for 15 minutes.
[0078] After electrophoresis, each dried sample was stained with a DNA intercalating fluorescent dye (SYBR Green solution). The cells were then observed in epifluorescence using an automated IN Cell Analyzer™ 2200 microscope image analyzer (GE Healthcare) (X10 objective). Upon excitation (ex 494 nm, em 524 nm), SYBR® Green bound to DNA emits green light. In healthy cells, the fluorescence is restricted to the nucleoids: undamaged DNA is supercoiled and therefore does not move much from the nucleoids under the influence of electric current. If DNA damage occurs, alkaline treatment unwinds the DNA, releasing fragments that migrate out of the cell when exposed to an electric field. The negatively charged DNA migrates to the anode, and the extrusion length is proportional to the relaxation of the supercoiled structure, which is an indicator of damage. When using alkaline electrophoresis conditions, the distribution of DNA between the tail and the comet head can be used to determine the extent of DNA damage.
[0079] Cell images were analyzed using OpenComet with ImageJ software. A minimum of 500 events were analyzed for each replicate.
[0080] FIG. 2 shows the corresponding results.
[0081] The DNA damage caused by UV light irradiation of human epidermal keratinocytes is identifiable. The tiron positive control can protect against DNA damage due to its known antioxidant properties, and therefore shows approximately 60% protective effect against DNA damage after UV irradiation. The substance of the present invention also shows a protective effect of more than 60%. This effect is not known for sphingolipids / ceramides, and cannot be demonstrated for the pure sphingoid base phytosphingosine (PS) in this test.
[0082] The following experiments are not shown in Figure 2: In the above setting, 2-hydroxy-3,3-dimethyl-hydroxybutyroylsphinganine exhibits a 24% protective effect at a concentration of 5 μM, and 2-hydroxy-3,3-dimethyl-hydroxybutyroylphytosphingosine exhibits a 39% protective effect at a concentration of 2 μM.
[0083] In the above setting, ceramide 3 (also known as ceramide NP) exhibits a protective effect of 12% at a concentration of 10 μM, and 3-hydroxypropioylphytosphingosine exhibits a protective effect of 13% at a concentration of 10 μM.
[0084] Example 7: In vivo data In the in vivo study, 24 subjects (male and female) were recruited to have their skin subjected to sun-stress. To ensure that the skin was subjected to sun-stress, the study was conducted from September to November, assuming that the skin would show the highest level of sun-stress at the end of the summer.
[0085] Subjects received either two different test formulations, each applied to one forearm, or one test formulation, applied to one forearm while the other forearm was left untreated (control). The test formulations were a vehicle and a formulation containing 0.1% hydroxybutyroyl phytosphingosine (hydroxybutyroyl PS). The various test combinations were randomly assigned to subjects.
[0086] The composition of the test formulation is shown in Table 1. Subjects applied the test formulation twice daily, in each case to the inside and outside of one forearm, for eight weeks. The following measurements on the forearms were taken before application began and after 2, 4 and 8 weeks: 1. Color measurement: Using a colorimeter probe (Skin-Colorimeter CL 400, Courage & Khazaka, Cologne), the parameter L was measured on the outer side of the forearm. * and ITA° were measured. * represents the black / white value of the skin and ITA° represents the skin tone. When the skin becomes lighter, both values show an increase. 2. Skin roughness: This parameter was measured using a special camera (Visioscan VC 98, Courage & Khazaka) on the inside of the forearm. This camera records a digital black and white image of the skin. The greyscale distribution of the image can be used to determine the skin roughness. 3. Dermal Density: Dermal density was measured by ultrasound on the outer forearm (SkinLab Combo, Cortex Technologies, Denmark). For this, a special probe transmits an ultrasound signal into the skin and records the reflection. This reflection can be used to determine a value for skin density. A decrease in skin density is especially indicated by skin areas that are very exposed to sunlight. [Table 1]
[0087] FIG. 3 shows the increase in ITA° after 2, 4 and 8 weeks of application of the test formulations.
[0088] Figure 4 shows the L after 2, 4 and 8 weeks of application of the test formulation. * This indicates an increase in
[0089] Color parameter L in Figures xy1 and xy2 *The increase in ITA° indicates that the skin has become lighter throughout the measurement period, with the increase in brightness being most pronounced on the skin areas treated with hydroxybutyroylphytosphingosine compared to the vehicle formulation or untreated controls. This was not due to the destruction of melanin in the skin in this case. Skin tanning is most pronounced at the end of the summer and then subsides in the fall as a result of the normal skin renewal cycle. This cycle is enhanced by hydroxybutyroylphytosphingosine, in which case the skin lightens more rapidly.
[0090] FIG. 5 shows the reduction in skin roughness after 2, 4 and 8 weeks of application of the test formulation.
[0091] From FIG. 5, it can be seen that the reduction in skin roughness is most pronounced for the test formulation containing hydroxybutyroyl phytosphingosine, both compared to the untreated control and especially compared to the vehicle. This confirms the skin color measurements: a characteristic feature of sun-stressed skin is an increase in skin roughness. This roughness also decreases towards autumn as a result of normal skin renewal. Hydroxybutyroyl phytosphingosine aids in the skin renewal cycle, so the reduction in skin roughness is more pronounced than for the vehicle formulation or the untreated control.
[0092] FIG. 6 shows the increase in skin density after 2, 4 and 8 weeks of application of the test formulation.
[0093] Skin areas with high exposure to sunlight show a decrease in skin density. Skin test results show that the skin density of hydroxybutyroyl phytosphingosine is already significantly increased after two weeks of use compared to untreated controls or vehicle.
[0094] The experiment is repeated in the same manner using 6-hydroxyhexanoylphytosphingosine (Example 1b), 2-hydroxy-3,3-dimethyl-hydroxybutyroylphinganine (Example 5b), ceramide 3 (also known as ceramide NP) and 3-hydroxypropioylphytosphingosine (Example 1c). [Table 2]
Claims
1. General formula I [Formula 1] [In the formula, R 1 is a hydrocarbon group having 2 to 54 carbon atoms, substituted with at least one group selected from -OH and -COOH, and optionally interrupted by at least one -O-; R 2 is H, phosphocholine, serine, ethanolamine or a sugar, X is CH=CH, CH 2 -CH 2 or CH 2 -HCOH, Y is selected from -OH and H; However, R 1 is a linear alkyl group substituted only with -OH groups at the ω positions, X is CH 2 -HCOH] sphingolipid.
2. R 1 is selected from linear or branched alkyl groups having 2 to 54 carbon atoms substituted with at least one group selected from -OH and -COOH; R 2 , Y are H, and / or X is CH 2 The sphingolipid according to claim 1, characterized in that it is -HCOH.
3. R 1 is selected from a hydrocarbon group having 2 to 54 carbon atoms substituted at the ω position with at least one group selected from -OH and -COOH; R 2 , Y is H, and / or X is CH 2 The sphingolipid according to claim 1 or 2, characterized in that it is -HCOH.
4. Hydroxybutyroyl Phytosphingosine [Case 2] , succinoylphytosphingosine [C3] , gluconoyl phytosphingosine [C4] , Lactobionoyl phytosphingosine [C5] , and 2-hydroxy-3,3-dimethyl-hydroxybutyroylphytosphingosine [C6] The sphingolipid according to claim 1 or 2, selected from the group consisting of
5. A sphingolipid as described in claim 1 or 2 for use in the treatment or prevention of cell damage.
6. 3. Cosmetic, non-therapeutic use of at least one sphingolipid according to claim 1 or 2 for preventing skin ageing caused by UV radiation.
7. A cosmetic formulation comprising at least one sphingolipid according to claim 1 or 2 in an amount of 0.02% to 1.50% by weight, the weight percentages being based on the total formulation.
8. 8. The cosmetic formulation according to claim 7, further comprising at least one UV photoprotective filter substance.
9. A method for producing the sphingolipid according to claim 1 or 2, I) a first component, represented by general formula II [C7] [In the formula, R 2b is H, phosphocholine, serine, ethanolamine or a sugar, X b is CH=CH, CH 2 -CH 2 or CH 2 -HCOH; II) a second component, of formula R 1b C.Y. b HCOOH [In the formula, R 1b is a hydrocarbon group having 2 to 54 carbon atoms, substituted with at least one group selected from -OH and -COOH, and optionally interrupted by at least one -O-; Y b is selected from -OH and H; III) reacting the first component with the second component to obtain a sphingolipid, and optionally IV) Purifying sphingolipids The method includes:
10. 10. The process according to claim 9, characterized in that process step III) is carried out in a temperature range from 40°C to 95°C.
11. A method for producing a sphingolipid according to claim 1 or 2, comprising the following steps: A) a first component, represented by general formula II [C8] [In the formula, R 2b is H, phosphocholine, serine, ethanolamine or a sugar, X b is CH=CH, CH 2 -CH 2 or CH 2 -HCOH; B) a second component, of formula R 1b C.Y. b HCOOH [In the formula, R 1b is a hydrocarbon group having 2 to 54 carbon atoms, substituted with at least one group selected from -OH and -COOH, and optionally interrupted by at least one -O-; Y bis selected from -OH and H; C) reacting the first component with the second component using at least one coupling reagent for activation of the hydroxycarboxylic acid to obtain a sphingolipid, and optionally D) Purifying sphingolipids The method includes:
12. 12. The process according to claim 11, characterized in that in process step C) the coupling reagent used is at least one selected from the group comprising dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-cyclohexyl-N'-(2'-morpholinoethyl)carbodiimide metho-p-toluenesulfonate, N-benzyl-N'-3'-dimethylaminopropylcarbodiimide hydrochloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N-ethylcarbodiimide hydrochloride and carbonyldiimidazole.
13. 12. The process according to claim 11, characterized in that in process step C) at least one catalyst is used which is selected from the group comprising N-ethyldiisopropylamine, trialkylamines, pyridine, 4-dimethylaminopyridine and hydroxybenzotriazole.
